Background. Lower breast density (BD) is associated with lower risk of breast cancer and may serve as a biomarker for the efficacy of chemopreventive strategies. This review explores parameters that are thought to be associated with lower BD. We conducted a systematic review of articles published to date using the PRISMA strategy. Articles that assessed change in BD with estrogen-receptor modulators (tamoxifene [TAM], raloxifene [RLX], and tibolone) and aromatase inhibitors (AIs), as well as cross-sectional and longitudinal studies (LSs) that assessed association between BD and physical activity (PA) or diet were reviewed. Results. Ten studies assessed change in BD with TAM; all reported TAM-mediated BD decreases. Change in BD with RLX was assessed by 11 studies; 3 reported a reduction in BD. Effect of tibolone was assessed by 5 RCTs; only 1 reported change in BD. AI-mediated BD reduction was reported by 3 out of 10 studies. The association between PA and BD was assessed by 21 studies; 4 reported an inverse association. The relationship between diet and BD was assessed in 34 studies. All studies on calcium and vitamin D as well as vegetable intake reported an inverse association with BD in premenopausal women. Two RCTs demonstrated BD reduction with a low-fat, high-carbohydrate intervention. Conclusion. TAM induces BD reduction; however, the effect of RLX, tibolone, and AIs on BD is unclear. Although data on association between diet and BD in adulthood are contradictory, intake of vegetables, vitamin D, and calcium appear to be associated with lower BD in premenopausal women.
Introduction
Breast cancer (BC) is the most frequently diagnosed female cancer, and the second leading cause of deaths related to cancer in women worldwide. 1 Risk factors such as aging, breast density (BD), lifestyle, and genetic parameters have all been implicated in breast carcinogenesis. 2, 3 Of these risk factors, BD has been shown to be very significant, especially in younger women. 4 Established BC risk factors associated with genetics and lifestyle are also confounders for BD through hormonal and genetic pathways and modify the relationship between BD and BC risk. 5 Breast density refers to the proportion of the breast that is composed of fibroglandular tissue and is represented by the radiopaque areas on a mammogram. 6, 7 Although BD is regarded as a strong risk factor for BC, it is still contentious whether it is an independent risk factor or whether it merely reflects opportunities for cancer to develop. Regardless of these contentions, high mammographic BD (MBD) has been shown to be associated with BC risk and interval cancer. 4 Importantly, BD is regarded as a modifiable risk factor for BC 8, 9 and, therefore, may be an important biomarker for the effect of interventions on BC risk.
Identifying the relationship between MBD and interventions that modify BD requires reliable and reproducible methods for MBD assessment. Currently, area-based and volumetric approaches exist for MBD assessment. 6, 7 The qualitative area-based methods classify MBD into different categories based on subjective opinion, using features such as area covered by dense tissue and ductal prominence. They include the Wolfe, Boyd and Tabẚr methods, along with the Visual Analogue Scale and breast imaging reporting and data system (BI-RADS). 6, 7 Semiautomated area-based methods such as planimetry, Cumulus, and Madena use thresholding and segmentation techniques to measure percentage mammographic density (PMD). Automated areabased methods use thresholding and/or statistical modeling to estimate PMD and include texture-based approaches, Autodensity, and MedDensity. 6 Volumetric approaches use statistical or physical modeling to calculate volumetric BD (VBD). Volumetric approaches include calibration techniques, dual-energy X-ray absorptiometry, Cumulus V, and 3 physics model-based volumetric techniques: Standard Mammographic Form, Volpara, and Quantra. 6, 7 Many studies have attempted to assess the relationship between BD and specific clinical interventions such as estrogen-receptor modulators, [8] [9] [10] [11] aromatase inhibitors (AIs), [12] [13] [14] [15] [16] [17] physical activity (PA), [18] [19] [20] [21] [22] [23] and diet. [24] [25] [26] [27] [28] [29] [30] [31] However, the nature and magnitude of the relationship between BD and these interventions is unclear. Furthermore, the category of women (age, ethnicity, body mass index [BMI] , and menopausal status) in which these parameters are more effective is unclear. This lack of clarity underscores the need for a review of interventions that are thought to have an impact on BD, given the role of BD as an intermediate and potentially modifiable risk factor for BC. 5, 8, 9 Increasingly, BD notification legislations have been passed in 22 states in the United States, 32 and BD details are being made available to screened women. The benefit of BD notification to women will only be accrued when such data are accompanied with clear information about BD and cancer as well as information about parameters that are associated with lower BD and cancer risk. Therefore, this review examines the effect of estrogen-receptor modulators such as tamoxifene (TAM), raloxifene (RLX), and tibolone as well as AIs such as letrozole, anastrozole, and exemestane on BD. It also explores the association between BD and parameters such as PA and diet.
Materials and Methods

Search Strategy
The Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) strategy was used to search for articles published to date using MEDLINE, EMBASE, CINAHL (Ebscohost), PubMed, Cochrane library, Web of Science, and Scopus databases. We also conducted a Google search, and reference lists of published articles were examined to identify additional articles not found in the database search. The search was conducted in the English language. To systematically search for literature of interest, a combination of search terms was used; these were thematically related to our hypothesis and also common themes identified through preliminary search of the literature. These were "breast density reduction interventions," "breast density modifiers," "breast density and estrogen-receptor modulators," "breast density and tamoxifene," "breast density and raloxifene," "breast density and tibolone," "breast density and letrozole," "breast density and anastrozole," "breast density and exemestane," " breast density and aromatase inhibitors," "breast density and physical activity," "exercise and breast density," "breast density and diet."
Inclusion Criteria
Articles were included if they were randomized controlled trials (RCTs), case-control studies (CCSs), or cohort studies (CSs) that investigated change in BD with interventions. Longitudinal studies (LSs) and cross-sectional studies (CSSs) that assessed association between BD and parameters such as PA and diet were also included. Articles were also included if they were published in the English language. Articles that did not fulfill the above criteria were excluded, as were reviews and case reports.
Data Synthesis
Data extraction was performed independently by 2 reviewers, with differences of opinion resolved by discussion. No article needed to be excluded for reasons of differences of opinion between reviewers; however, had consensus not been reached, articles would have been excluded. For each study, reviewers extracted information using the Participant Intervention Comparator and Outcomes (PICOS) method ( Table 1 ). Studies that assessed BD from RCTs or were a subset of RCTs were considered RCTs in the current review. Studies were qualitatively assessed for quality and risk of bias based on study-specific design (clarity of protocol, assessment and report of compliance, blinding of outcome assessors, and outcome measures); this enabled us to appraise the conduct of each study. Table 1 shows eligibility criteria for inclusion of studies.
Results
The search strategy identified 1853 publications, from which 156 eligible articles were found. Of these, 48 were duplicates, and 21 did not fulfil the inclusion criteria and were excluded, resulting in 87 articles that fulfilled the inclusion criteria. Of the articles that fulfilled inclusion criteria, 22 were on selective estrogen-receptor modulators (SERMs), 2 were on SERMs and AIs, 8 were on AIs alone, 21 were on PA, and 34 were on diet ( Figure 1 ).
Of the studies on estrogen-receptor modulators, 10 assessed change in BD with TAM intervention and included 1 RCT, 10 2 nested CCSs, 8,9 1 CS, 11 and 6 post hoc analyses of RCTs. [33] [34] [35] [36] [37] [38] The sample sizes of the 10 studies ranged from 16 to 1065 (n = 2877). Among the studies, 7 included premenopausal and postmenopausal women, with heterogeneity in criteria for ascertaining menopausal status. Most of the studies administered 20 mg of TAM per day, and total duration of TAM administration varied from 1.5 to 6 years. Also, 7 studies used area-based qualitative and/or quantitative approaches for MBD assessment, and 1 assessed fibroglandular volume with MRI. Only 4 studies adjusted for confounding factors that affect BD. [8] [9] [10] 35 All studies reported TAM-mediated BD decreases (Table 2) .
A total of 9 studies assessed change in BD with RLX alone, [39] [40] [41] [42] [43] [44] [45] [46] [47] and 2 studies assessed tibolone and RLX intervention. 48, 49 The sample size ranged from 27 to 444 (n = 2005), and 8 of the 9 studies assessed postmenopausal women. Most of the studies administered 60 mg of RLX per day, and the duration of the RLX administration varied from 3 months to 3 years. Area-based methods were used for MBD assessment in a majority of the studies, and 1 study measured fibroglandular volume with MRI. There was a paucity of information on BD confounders in most of the studies. Of all RLX studies reviewed, only 3 reported a significant reduction in BD (Table 2) . 40, 41, 49 There were 5 RCTs that assessed change in BD with tibolone intervention. [48] [49] [50] [51] [52] Ages of participants ranged from 41 to 70 years, and the sample size ranged from 37 to 177 (n = 665). Tibolone administration was 2.5 mg/d, and duration of administration was 1 year. Three studies performed subjective MBD assessment, 1 used Cumulus, and 1 performed VBD assessment. Only the study that measured VBD adjusted for confounders and reported a significant tibolone-mediated BD reduction. 49 Changes in BD with AIs (letrozole, 2.5 mg/d; anastrozole, 1 mg/d; exemestane, 25 mg/d) were assessed in 10 studies. [13] [14] [15] [16] [17] [53] [54] [55] [56] Four of the studies used letrozole alone; there was 1 study each on anastrozole and exemestane, and others combined 2 of the 3 AIs. Of these, 4 were prospective arm trials and 3 were RCTs. The sample size varied from 16 to 1065 (n = 2110), and the age of participants ranged from 24 to 77 years, with 80% of the studies involving postmenopausal women alone. The duration of administration ranged from 6 months to 2 years. Among the studies, 7 assessed MBD using area-based computerassisted methods, and the remaining studies used an areabased subjective approach alone or in combination with area-based computer-assisted methods. There was little or no adjustment for BD confounding factors in most of the studies. Only 3 out of the 10 studies reported statistically significant reduction in BD with AIs ( Table 2) . 15, 17, 54 The association between PA and BD was assessed in 21 studies. [18] [19] [20] [21] [22] [23] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] Of these, 71% were CSSs, and the sample size ranged from 95 to 2720 (n = 20 424). Association between PA and BD was evaluated within 5 years prior to date of mammographic examination in 71% of the studies, and 29% assessed this association more than 5 years prior to mammography date. In all, 5 studies investigated the association of childhood and adolescent PA with BD in adulthood. Also, 11 studies assessed nonoccupational PA; 7 assessed household, occupational, and recreational PA; and 2 assessed life-course PA ( Table 3 ). Qualitative assessment of MBD was performed in 7 studies, and area-based quantitative approaches were used for PMD assessment in 14 studies. A significant percentage (81%) of the studies found no association between PA and BD 22, 23, [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] ; 19% of the studies reported a statistically significant inverse association between PA and BD in perimenopausal and postmenopausal women with BMI >25 kg/m 2 . [18] [19] [20] [21] The relationship between diet and BD was assessed in 34 studies: 59% were CSSs on the association between diet and BD, and 27% were RCTs that assessed change in BD with dietary interventions (Table 4 ). The sample size ranged from 30 to 2252 (n = 24 579). Of these, 27 studies assessed diet in adults aged 25 to 79 years, [24] [25] [26] 28, 29, 31, and 7 studies assessed the association of childhood and/or adolescent diet (4 to 18 years) with BD in adult life. 27, 64, 68, [93] [94] [95] [96] Of the studies in adults, 5 evaluated calcium and vitamin D (≥750 mg/d and ≥100 IU/d respectively), 4 assessed circulating vitamin D-25(OH) D-and 6 assessed isoflavone. Four studies assessed dietary fats 26, [80] [81] [82] ; 3 assessed a low-fat, high-carbohydrate diet 25, 29, 83 ; and 4 assessed carbohydrates and proteins. [80] [81] [82] 90 Two studies assessed vegetables, 26, 73 and 2 assessed Mediterranean diets (Med-diets) and multivitamin-multimineral supplements (M-M supplements). 24, 92 Of the 7 studies that assessed childhood and adolescent diet, 3 were on dietary patterns, 64, 84, 95 and other studies were on calorie restriction, 96 alcohol, 93 dietary vitamin D and calcium, 94 and a low-fat diet. 27 A majority of the studies assessed BD with area-based methods such as Cumulus and qualitative approaches. No association was found between childhood or adolescent diet and BD in adulthood. 27, 64, 68, [93] [94] [95] In adults, all 5 studies on calcium and vitamin D reported an inverse association with BD in premenopausal women but not in postmenopausal women. 72, 73, 76, 77, 84 All RCTs of isoflavone demonstrated no change in BD, 31, [86] [87] [88] [89] and all CSSs reported no inverse association between dietary fat and BD. 26, [80] [81] [82] The 2 RCTs on low-fat, high-carbohydrate intervention found statistically significant BD decreases, 25, 83 and no further change was noted in a 4-year post hoc analysis of 1 RCT. 29 Studies on protein and carbohydrate intake and BD generated conflicting results, with 2 reporting higher BD, 82,90 1 demonstrating an inverse association, 80 and 1 reporting no association with BD. 81 The 2 studies on vegetable intake in adulthood reported an inverse association with BD. 26, 73 Intake of Med-diets and M-M supplements also demonstrated conflicting results, with one reporting lower BD for Med-diet and M-M supplements in postmenopausal women alone (P < .05) 92 and the other demonstrating higher BD in premenopausal women but not in postmenopausal women (Table 4 ). 24
Discussion
One encouraging attribute of BD is that it can be altered. 8 Because most determinants of BD and BC are interrelated and interdependent, 5 it is logical that parameters that lower BD may lower BC risk. Many parameters are thought to alter BD; however, this review focuses on SERMs, AIs, PA, and diet. Estrogen plays a critical role in BD and increased BC risk 5 ; therefore, it is intuitive that interventions that decrease estrogen bioavailability may lower BD. A few substances with strong binding affinity for estrogen receptors such as SERMs have been identified to antagonize the action of estrogen on breast tissue through inhibition of 17β-estradiol activity. 97 SERMs also decrease insulin-like growth factor (IGF)-1 levels and increase IGF binding protein (IGFBP) and sex hormone binding-globulin. 8, 9, 15 Other substances (AIs) inhibit the production of estrogen by aromatase. 15, 56 Evidence shows that TAM mediates BD reduction in both premenopausal and postmenopausal women, but no concrete evidence exists for BD reduction with RLX, tibolone, letrozole, anastrozole, or exemestane ( Table 2 ). The BD reduction in TAM studies might be explained by the prevalence of premenopausal women as shown by the stronger BD decreases in premenopausal women. Most of the AIs, tibolone, and RLX studies were performed in postmenopausal women. Because menopause is associated with tissue involution, 98 postmenopausal breast tissue may not be responsive to AIs and RLX therapies.
A few limitations are noted in studies on antiestrogen agents. About 80% of the studies on TAM and tibolone did not adjust for BD confounders. Two of the studies on estrogen modulators had very small sample sizes, 11, 17 and 1 study 99 reported duration of treatment but not dosage administered. There was variability in age, populations, and sample size between studies, thus making comparison of studies difficult. A majority of the studies did not assess the consistency of MBD assessments, and 90% of the studies used area-based approaches for MBD assessment, which may not detect change in BD when the quantity of dense tissue changes but the dense area remains unchanged. Significant changes in BD with 3 different estrogenreceptor modulators were demonstrated where VBD assessment was performed 11, 40, 49 and emphasize the need for further studies using volumetric methods to assess the effect of RLX, tibolone, and AIs on BD in premenopausal women. Thus, variability in MBD assessment continues to be a confounding factor in studies assessing the impact of interventions on BD, as demonstrated by the heterogeneity in results obtained in the same patients when different MBD measurement approaches were used. 35, 40, 54 PA alters BMI by reducing adiposity and increasing muscle mass, and the association between BMI, BD, and cancer is well established. 100 However, the evidence for the association between PA and BD is conflicting. Of the 21 studies, 81%, including a RCT of aerobic exercise on BD, 23 found no association between PA and BD. It is well established that BMI and postmenopausal status are negative confounders for BD. 100 BMI was found to attenuate the association between PA and BD, but only 9 studies adjusted for menopausal status; 95% of the studies did not report whether participants were premenopausal or postmenopausal at the time of PA, and 1 study 70 did not specify the timing of PA. There was heterogeneity in the type, duration, and intensity of PA, making comparison of results difficult. The only RCT that assessed change in BD with aerobic exercise was in postmenopausal women. Involution of the breast and depletion of sex hormones and growth factors is common in postmenopausal women. 5, 98 Because exercise acts through these hormonal agents, it is unsurprising that no change was noted in BD with aerobic exercise in postmenopausal women. About 90% of the studies assessed Caucasian women, limiting the generalization of results to other ethnic populations. As yet, there is no evidence to suggest that PA is associated with lower BD. Nonetheless, because PA is inversely related to serum IGF-1, estrogen, and progesterone bioavailability and reduction in their serum concentration reduces cell proliferation and exposure to carcinogens, PA is a controllable, important BC risk mitigation agent.
Although evidence for the association between diet and BD is also contradictory, 27, 64, 68, [93] [94] [95] [96] intake of vitamin D and calcium; a low-fat, high-carbohydrate diet; and vegetables appears to be associated with lower BD, mostly in premenopausal women (Table 4 ). Calcium and vitamin D play an important role in the modulation of epithelial cell growth, proliferation, and differentiation. 101 The inverse association between these food sources and BD in premenopausal women is stronger at higher threshold consumption and among women with high concentrations of IGF-I or IGFBP-3. 77 Lower BD from calcium and vitamin D intake has been attributed to antioxidant activity 101 and inhibition of IGFs. 77 Premenopausal, compared with postmenopausal, women have more proliferating cells and mitogens implicated in BD increases, 5, 8, 77 which is perhaps the reason for the inverse association between calcium and vitamin D with BD in premenopausal women only. Isoflavone consumption has been shown to be associated with lower cancer incidence 102 but not BD. 31, [86] [87] [88] [89] A recent LS shows that soyproduct consumers who metabolize daidzein manufactured by intestinal bacteria to equol (a nonsteroidal estrogen) demonstrate slightly lower BD than non-equol producers. 91 This suggests that the metabolism of a specific diet may influence its association with BD and needs to be explored. Isoflavones reduce the effects of mitogens and mutagens through increases in antioxidant activity and sex hormonebinding globulin serum bioactivity, 102 and these 2 properties reduce cell proliferation associated with BD increases. Isoflavone studies are limited by the area-based assessment of MBD and inadequate adjustment for BD confounders.
The literature on the association between carbohydrates and proteins with BD also presents conflicting outcomes: direct association, 82 inverse association, 80 and no association. 81 However, RCTs on low-fat, high-carbohydrate diet have shown an inverse association with BD in premenopausal and postmenopausal women. 25, 29 There is evidence that the fiber make-up of carbohydrates influences the IGF/ IGFBP sequence and oxidative stress. 103 Therefore, varying fiber content in the different sources of carbohydrates may differentially influence growth factors responsible for BD variations, and this may be the reason for the inconsistent relationship between carbohydrate intake and BD.
Vegetables and carotene inhibit cell proliferation and IGF-1, 104 and these may be the reasons for their association with lower BD in premenopausal and postmenopausal women. 26, 73 Although regular use of M-M supplements has generated different outcomes, these supplements contain antioxidants that reduce the activity of mitogens responsible for BD increases 24 and, therefore, need to be further investigated.
Generally, the reliance of CSSs on questionnaires whose reliability can be diminished by memory deficiency makes it difficult to measure the extent of exposure to dietary factors. 105 The association between a specific diet and BD may also be attenuated if such food is consumed in combination with other counteracting food substances and if intake occurred before mammogenesis. Therefore, RCTs using VBD measurement approaches may provide more accurate evidence for the impact of interventions on BD. The literature demonstrates that antidiabetes agents such as metformin inhibit IGF-1 and insulin/IGF chain and alter metabolic processes. 106 These processes are associated with reduction in cell proliferation, 106 which may lower BD. Thus, it may be important to assess the effect of antidiabetes agents and changes in glucose homeostasis on BD. Finally and encouragingly, change in BD over time is consistent with change in BC risk, 107, 108 and reduced BD is associated with a reduced risk of BC 108, 109 and death from the disease. 110 Therefore, BD may have potential utility as a biomarker for the efficacy of chemopreventive interventions.
Conclusion
There is substantial evidence that BD is potentially reducible. Tamoxifen reduces BD; however, the effect of RLX, tibolone, and AIs on BD is still unclear. There is no evidence for association of PA and childhood or adolescent diet with BD. Although data on the association between dietary factors and BD are conflicting, intake of vegetables, vitamin D, and calcium in adulthood is associated with lower BD in premenopausal women. It is hoped that lowering BD with interventions may lower BC risk and improve early detection of BC with mammography. However, these benefits can only be amassed if women are adequately informed about BD and BC risk mitigation strategies. Implementation of these strategies may hold the key to reducing the risk of BC.
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